Dianthus Therapeutics, Inc. /DE/
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
CARR EDWARD (CHIEF ACCOUNTING OFFICER) sold 20,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.38 ($100.43–$104.39, $2.03M total) across 5 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
Analysts initiated coverage on five companies: Keybanc rated PPG Industries (PPG) Overweight with a $133 target, Bernstein rated Shopify (SHOP) Outperform with a $160 target, Mizuho rated Chesapeake Utilities (CPK) Outperform with a $150 target, Piper Sandler rated Global Payments (GPN) Neutral with a $101 target, and JP Morgan rated Dianthus Therapeutics (DNTH) Overweight with a $135 target. All stocks closed lower than their respective targets on Thursday.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning DNTH (Dianthus Therapeutics, Inc. /DE/). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DNTH coverage spans financial news, insider activity and earnings.
In the last 30 days, DNTH insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($2.0M). The most active reporter was CARR EDWARD, CHIEF ACCOUNTING OFFICER, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
May see modest price appreciation.
Insider sell may pressure the stock lower in the short term.
Biotech coverage may spark speculative interest.
Biotech initiation could spark speculative interest.
Positive interim data may boost DNTH valuation; higher R&D spend increases loss but cash runway remains strong.
AlphAI scores every news story that mentions DNTH with an AI model for sentiment and relevance, and aggregates insider trades from Dianthus Therapeutics, Inc. /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
William Blair updated its October Analyst Conviction List, adding 12 stocks including Casey’s General Stores (CASY) and Remitly Global (RELY), and removing six. Remitly reported Q2 2026 earnings of $0.93 per share, beating estimates, with revenue up 20% YoY. Analysts raised price targets for RELY to $30 and $31, citing strong performance and guidance.
2 min readCARR EDWARD (CHIEF ACCOUNTING OFFICER) sold 20,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.38 ($100.43–$104.39, $2.03M total) across 5 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readAnalysts initiated coverage on five companies: Keybanc rated PPG Industries (PPG) Overweight with a $133 target, Bernstein rated Shopify (SHOP) Outperform with a $160 target, Mizuho rated Chesapeake Utilities (CPK) Outperform with a $150 target, Piper Sandler rated Global Payments (GPN) Neutral with a $101 target, and JP Morgan rated Dianthus Therapeutics (DNTH) Overweight with a $135 target. All stocks closed lower than their respective targets on Thursday.
2 min readAnalysts initiated or updated coverage on several companies. Piper Sandler initiated Q2 Holdings as overweight, citing its growth potential. Bernstein initiated Shopify as outperform, highlighting its AI positioning. RBC initiated Dell as outperform with a $640 price target, citing AI infrastructure demand. UBS initiated Korsana Biosciences as buy with a $55 price target. Other notable mentions include Nvidia, SpaceX, Tesla, Palantir, and Oracle.
3 min readDianthus Therapeutics (DNTH) reported Q2 2026 results, highlighting clinical trial progress. Claseprubart showed a 75% response rate in a Phase 3 trial for chronic inflammatory demyelinating polyneuropathy. The company also advanced trials for multifocal motor neuropathy and generalized myasthenia gravis. R&D costs rose to $48.7M, with a net loss of $50.2M. DNTH has $1.2B in cash, funding operations into 2030.
2 min readAnalysts made several rating changes: Bernstein upgraded Ormat (ORA) to Market Perform, Morgan Stanley upgraded Shell (SHEL) to Overweight with a $101.30 target, Barclays upgraded W.P. Carey (WPC) to Equal Weight, Baird upgraded Sonida Senior Living (SNDA) to Outperform with a $43 target, and Piper Sandler upgraded Simmons First National (SFNC) to Overweight with a $27.50 target. Canaccord downgraded UiPath (PATH) to Hold with a $17 target, Craig-Hallum downgraded Ambarella (AMBA) to Hold with a
3 min readAnalysts made several calls: Goldman Sachs reiterated Tesla as neutral, citing Cybercab's cost benefits. Bernstein kept Apple as outperform, noting market share gains. Baird upgraded Sonida Senior Living to outperform. Morgan Stanley upgraded Shell to overweight, expecting acceleration. Piper Sandler upgraded Simmons First National to overweight. Goldman upgraded Vodafone to buy. B. Riley initiated Infleqtion as buy. William Blair kept Nvidia as outperform, approving its Hugging Face acquisition
3 min readRandhawa Simrat (EVP, Head of R&D) sold 23,124 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $106.41 ($105.19–$106.74, $2.46M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readMcGeorge Anne sold 7,750 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $109.01 ($107.58–$111.41, $0.84M total) across 5 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min readVeness Adam M (SVP, General Counsel and Sec.) sold 20,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $110.44 ($110.38–$111.18, $2.21M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.
1 min read
